*GG*
senior member
- Messages
- 6,389
- Location
- Concord, NH
Columbia University in New York City is seeking three study participants for a double-blind, placebo controlled clinical trial of idebenone in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes).
The Phase IIa study will compare two different doses of an experimental medication, idebenone, administered over a one month period to determine the efficacy of the drug. People with MELAS and the 3243 mutation, aged 8-65 years, may be eligible.
The main goal of the clinical trial is to determine if idebenone has an effect on brain lactate as measured by magnetic resonance spectroscopy (MRS). MRS is done in an MRI scanner, and is safe and typically well tolerated.
An additional goal is to study the safety and tolerability of idebenone in people with MELAS. If you or a family member would like more information regarding this study please see our website or contact the Research Coordinator, Kris Engelstad, at 212.305.6834. Click here to visit the trial website.
http://giblinlab.org/studies.html
The Phase IIa study will compare two different doses of an experimental medication, idebenone, administered over a one month period to determine the efficacy of the drug. People with MELAS and the 3243 mutation, aged 8-65 years, may be eligible.
The main goal of the clinical trial is to determine if idebenone has an effect on brain lactate as measured by magnetic resonance spectroscopy (MRS). MRS is done in an MRI scanner, and is safe and typically well tolerated.
An additional goal is to study the safety and tolerability of idebenone in people with MELAS. If you or a family member would like more information regarding this study please see our website or contact the Research Coordinator, Kris Engelstad, at 212.305.6834. Click here to visit the trial website.
http://giblinlab.org/studies.html